Jefferies Maintains Bullish Stance on Infinity Pharmaceutical (INFI) Following ASCO Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Infinity Reports Phase 1 Data Showing Clinical Activity of Duvelisib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
May 31, 2015 9:30 AM EDTClinical Activity Observed in High-Risk CLL Patients
New Translational Data Provide Further Insight Into the Role of PI3K-Delta and PI3K-Gamma Inhibition in Hematologic Malignancies
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced new clinical data for... More
